Navigating market access for DTx in France to maximize their impact

OpusLine part of Accenture Point of View – Life Science Strategy & Consulting

The combination of medical and biological knowledge and other disciplines such as mathematics, physics, or computer science, allows us to explore an important new field of innovation in health: digital. The COVID-19 crisis acted as an accelerator in its adoption: 60% of patients are ready to use it more to manage their disease. The global digital health market is attracting the industry and is now growing rapidly. It is estimated to be worth more than $234.5 billion by 2023. Within digital health, digital therapeutics (DTx) is also a fast-growing field. They represent the smallest part of digital health, about $2.42 billion in 2020, (2,6% of digital health), but its potential could be significant: it is estimated to grow by 570% by 2027 to reach $13.8 billion. Regulators and payers are looking into ways to integrate DTx into the healthcare system. In the meantime, Pharmaceutical companies see DTx as an opportunity to enhance their value proposition and improve patient care. In a context where the reimbursement of digital solutions is becoming clearer in France, we wanted to explore in this study the pathways to the DTx market in France, to shed light on the ongoing dynamics and to give players some keys to understanding the environment. Traditionally, digital health is broken down into 3 families:

Defining DTx more precisely is key to developping frameworks and market access pathways.  In light of the current environment and on-going discussions, we believe there are 6 criteria allowing to define what a DTx solution is.

 

Penetrating this fast-evolving market for life science players presents significant strategic and operational challenges.

 

The economic model for these solutions will certainly be the most strategic one. Economic models exist in France but their business potential remains unclear.

Regarding the national/regional public funding, which is considered as the gold standard in France, uncertainties are strong. French healthcare authorities are working to provide a framework to assess value of digital solutions and get them reimbursed. But they tend to think functionality by functionality, whereas manufacturers generally adopt a user or product centric approach. Today, several complementary market access routes coexist with various requirements and outcomes.


Our study deepdives into each one of them, providing concrete illustrations.

 

From our experience and research, key dynamics will shape the DTX market’s future

  • The value assessment framework for each technology should be adapted (A new framework is required to adapt value assessment for each technology) 
  • The exit from experimental funding routes needs to be clarified
  • Levers to ensure the user adoption of DTx need to be found
  • As for drugs, harmonization at European level is to be anticipated

From a pharma company standpoint, maximizing business potential will be the key challenge, and will require to:

  • Clearly define the indication, the target population, and the conditions of use
  • Match the DTx with the existing standards by identifying what the authorities value the most
  • Build from the design phase a data collection program in line with what is expected from the use of the DTx

 

Feel free to download the study as a PDF and for more information, contact us :

Retour à l’ensemble des actualités